[New insights into the epidemiology of immune thrombocytopenia in adult patients: Impact for clinical practice]

G Moulis; T Comont; D Adoue

doi:10.1016/j.revmed.2020.05.018

[New insights into the epidemiology of immune thrombocytopenia in adult patients: Impact for clinical practice]

Rev Med Interne. 2021 Jan;42(1):11-15. doi: 10.1016/j.revmed.2020.05.018. Epub 2020 Aug 11.

[Article in French]

Authors

G Moulis¹, T Comont², D Adoue²

Affiliations

¹ Service de Médecine Interne, CHU de Toulouse, France; UMR 1027 INSERM, Université de Toulouse, France; CIC 1436, CHU de Toulouse, France. Electronic address: [email protected].
² Service de Médecine Interne, Institut Universitaire du Cancer de Toulouse- Oncopôle, France.

PMID: 32798089
DOI: 10.1016/j.revmed.2020.05.018

Abstract

New insights into immune thrombocytopenia (ITP) epidemiology in adult patients highlight three main outcomes of morbidity and mortality: bleeding, infection and thrombosis. This review depicts current evidence about incidence and risk factors of bleeding, infection and thrombosis as well as predictors of chronicity, and shows how this assessment impacts the choice of ITP second-line treatment at the individual-level basis.

Keywords: Clinical practice; Epidemiology; Epidémiologie; Immune thrombocytopenia; Pratique clinique; Thrombopénie immunologique.

Publication types

Review

MeSH terms

Adult
Hemorrhage
Humans
Incidence
Purpura, Thrombocytopenic, Idiopathic* / diagnosis
Purpura, Thrombocytopenic, Idiopathic* / epidemiology
Purpura, Thrombocytopenic, Idiopathic* / therapy
Thrombocytopenia*
Thrombosis*